#1 Clinical Trials Search in Europe

Ascorbic Acid Bp

This article discusses the use of Ascorbic Acid BP (also known as Vitamin C) in clinical trials, specifically as part of a multivitamin formulation called Concavit Capsules. While the main focus of the trial is on a different drug (eplontersen) for treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), the multivitamin containing Ascorbic Acid BP is mentioned as a supplementary treatment. We’ll explore the potential benefits and implications of using this vitamin formulation in cardiovascular health research.

Table of Contents

What is ASCORBIC ACID BP?

ASCORBIC ACID BP, also known as Vitamin C, is an essential nutrient that plays a crucial role in various bodily functions. It is one of the active ingredients in a medication called Concavit Capsules[1]. The “BP” in the name stands for “British Pharmacopoeia,” which indicates that the substance meets specific quality standards.

Medical Uses of ASCORBIC ACID BP

While the clinical trial data provided doesn’t specifically focus on ASCORBIC ACID BP alone, we can discuss its general uses and importance as part of a multivitamin formulation:

  • Antioxidant properties: ASCORBIC ACID BP acts as an antioxidant, helping to protect cells from damage caused by free radicals.
  • Immune system support: It plays a vital role in supporting the immune system, potentially helping the body fight off infections.
  • Collagen synthesis: ASCORBIC ACID BP is essential for the production of collagen, a protein important for skin health, wound healing, and maintaining healthy blood vessels.
  • Iron absorption: It aids in the absorption of iron from plant-based sources, which can be beneficial for preventing anemia.

How is ASCORBIC ACID BP Administered?

According to the information provided, ASCORBIC ACID BP is administered as part of Concavit Capsules. These are soft capsules intended for oral use[1]. This means the medication is taken by mouth and swallowed.

Dosage Information

While specific dosage information for ASCORBIC ACID BP is not provided, the clinical trial data mentions some general dosage details for Concavit Capsules:

  • Maximum daily dose: 3000 IU (International Units)[1]
  • Maximum total dose: 3,285,000 IU[1]
  • Maximum treatment period: 36 months (3 years)[1]

It’s important to note that these dosage details are for the entire Concavit Capsules formulation, not just the ASCORBIC ACID BP component. Always follow your healthcare provider’s instructions regarding dosage and duration of treatment.

Other Ingredients in Concavit Capsules

ASCORBIC ACID BP is one of several active ingredients in Concavit Capsules. The other components include[1]:

  • Ergocalciferol BP (Vitamin D2)
  • Nicotinamide BP (Vitamin B3)
  • Riboflavin BP (Vitamin B2)
  • All-rac-alpha-tocopheryl acetate BP (Vitamin E)
  • Calcium pantothenate BP (Vitamin B5)
  • Thiamine nitrate BP (Vitamin B1)
  • Vitamin A BP
  • Pyridoxine hydrochloride BP (Vitamin B6)

This combination of vitamins suggests that Concavit Capsules are a multivitamin supplement designed to provide a range of essential nutrients.

Important Considerations

When taking any medication or supplement containing ASCORBIC ACID BP, keep the following in mind:

  • Consult your healthcare provider: Always discuss with your doctor before starting any new supplement regimen, especially if you have existing health conditions or are taking other medications.
  • Follow dosage instructions: Take the medication as prescribed by your healthcare provider. Do not exceed the recommended dose.
  • Be aware of potential interactions: Vitamin C can interact with certain medications and may affect the absorption of other nutrients. Inform your healthcare provider about all medications and supplements you’re taking.
  • Monitor for side effects: While vitamin C is generally considered safe, high doses can cause side effects such as digestive discomfort or diarrhea. Report any unusual symptoms to your healthcare provider.

Remember, while ASCORBIC ACID BP (Vitamin C) is an important nutrient, it’s just one component of a balanced diet and healthy lifestyle. Always prioritize a varied, nutrient-rich diet and consult with healthcare professionals for personalized advice on supplementation.

Aspect Details
Main Drug Studied Eplontersen
Condition Studied Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Multivitamin Used Concavit Capsules (containing Ascorbic Acid BP)
Administration Route Oral
Maximum Daily Dose 3000 IU
Maximum Total Dose 3,285,000 IU
Treatment Duration Up to 36 months
Study Type Open-Label Extension
Primary Objectives Evaluate safety and tolerability of extended eplontersen dosing
Secondary Objectives Assess efficacy parameters and biomarkers

FAQ

  • What is Ascorbic Acid BP and why is it used in clinical trials? Ascorbic Acid BP, also known as Vitamin C, is an essential nutrient used in clinical trials as part of multivitamin formulations. In this case, it's a component of Concavit Capsules, which are being used alongside the main drug being studied for cardiovascular health.
  • What is the main condition being studied in this clinical trial? The main condition being studied is transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a type of heart disease. The trial is primarily focused on evaluating a drug called eplontersen for treating this condition.
  • How is the multivitamin containing Ascorbic Acid BP administered in this trial? The multivitamin formulation containing Ascorbic Acid BP, called Concavit Capsules, is administered orally. The maximum daily dose is 3000 IU (international units), with a maximum total dose of 3,285,000 IU over the course of the trial.
  • What other vitamins are included in the Concavit Capsules along with Ascorbic Acid BP? Concavit Capsules contain several other vitamins and nutrients along with Ascorbic Acid BP, including Ergocalciferol (Vitamin D2), Nicotinamide, Riboflavin (Vitamin B2), Tocopheryl Acetate (Vitamin E), Calcium Pantothenate, Thiamine Nitrate (Vitamin B1), Vitamin A, and Pyridoxine Hydrochloride (Vitamin B6).
  • What is the duration of treatment with the multivitamin in this trial? The maximum treatment period for the multivitamin formulation containing Ascorbic Acid BP is 36 months, which is equivalent to 3 years.

Ongoing Clinical Trials on Ascorbic Acid Bp

  • Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

Glossary

  • Ascorbic Acid BP: Also known as Vitamin C, it's an essential nutrient that acts as an antioxidant and plays a role in immune function and collagen synthesis.
  • Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM): A type of heart disease caused by the buildup of abnormal proteins (amyloids) in the heart muscle, leading to heart failure.
  • Eplontersen: The main drug being studied in this clinical trial for the treatment of ATTR-CM.
  • Open-Label Extension Study: A type of clinical trial where both researchers and participants know which treatment is being administered, often following a previous study to gather long-term data.
  • Multivitamin: A supplement containing multiple vitamins and sometimes minerals, designed to provide essential nutrients that may be missing from a person's diet.
  • International Unit (IU): A unit of measurement for the amount of a substance, based on its biological activity or effect. It's commonly used for vitamins and hormones.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track the progress of a disease or the effects of treatment.
  • Echocardiogram (ECHO): A test that uses sound waves to create images of the heart, allowing doctors to evaluate heart function and structure.
  • Quality of Life Assessment: Questionnaires or tests designed to measure a person's overall well-being and ability to function in daily life, often used in clinical trials to assess treatment effects.

References

  1. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-eplontersen-for-adults-with-transthyretin-mediated-amyloid-cardiomyopathy/